한올바이오파마 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 국민연금공단, was filed 02 Jul 2026.
한올바이오파마: what insiders have been doing
This page follows insider dealings at 한올바이오파마 as filed with DART (FSS), a company from the Health Care sector. From 2 November 2025 to 2 November 2026, the disclosure feed for 한올바이오파마 logged 8 filings by 5 insiders.
Open-market activity splits into 6 purchases totalling €18.9M and 1 sale; 4 insiders sit on the buying side and 1 insider on the selling side. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder and 1 chief executive. Biggest ticket of the year: €17.7M, bought by 국민연금공단 and made public on 1 April 2026 (0.96% of market cap).
Within a 30-day window, 2 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 2 July 2026, 129 days ago. Filings reach the DART (FSS) feed a median of 6 days after the trade. That lag is the time during which only the insider knows about the trade.
Across the 2,655 companies tracked on its exchange, the median is 7 filings; at 8 filings, this issuer sits above that mark. Our records for 한올바이오파마 go back to 2021, with 19 purchases and 13 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -15.4%Entry ₩44,350 · Close 30 Oct 2026 ₩37,500
- -15.4%Entry ₩44,350 · Close 30 Oct 2026 ₩37,500
- -19.9%Entry ₩46,800 · Close 30 Oct 2026 ₩37,500
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 415,021 sharesShareKRXDART:20260702000236Canonical exit: 30 Sept 2026 (T+90)
- 649,446 sharesKRXDART:20260701000222Canonical exit: 29 Sept 2026 (T+90)
- 13,334 shares@ ₩23,363.000.0100% mcap100.0% of flowShareKRXDART:20260506000621Canonical exit: 4 Aug 2026 (T+90)
- 3,334 shares@ ₩32,600.000.0035% mcap100.0% of flowShareKRXDART:20260506000598Canonical exit: 4 Aug 2026 (T+90)
- 7,954 shares@ ₩39,636.05180.070% mcap100.0% of flowShareKRXDART:20260506000611
- 5,248,964 shares@ ₩56,195.000.053% mcap5.2% of flowShareKRXDART:20260407002729Canonical exit: 1 Jul 2026 (T+90)
- 531,342 shares0.96% mcap94.8% of flowKRXDART:20260401004313Canonical exit: 10 Jun 2026 (T+90)
- 536,532 sharesKRXDART:20260102000211
- 1,000 sharesShareKRXDART:20251029000169Canonical exit: 27 Jan 2026 (T+90)
- 1,499 sharesShareKRXDART:20250602000961Canonical exit: 31 Aug 2025 (T+90)
- 13,333 sharesShareKRXDART:20250430001334Canonical exit: 29 Jul 2025 (T+90)
- 65,493 sharesShareKRXDART:20250108000030Canonical exit: 8 Apr 2025 (T+90)
- 5,246,376 sharesShareKRXDART:20241226000479Canonical exit: 26 Mar 2025 (T+90)
- 7,272 sharesShareKRXDART:20241120000287
- 5,227,501 sharesShareKRXDART:20241115000203Canonical exit: 13 Feb 2025 (T+90)
- 15,244 sharesShareKRXDART:20241112000246
- 5,236,258 sharesShareKRXDART:20241107000117Canonical exit: 5 Feb 2025 (T+90)
- 333 sharesShareKRXDART:20241106000219Canonical exit: 4 Feb 2025 (T+90)
- 6,405 sharesShareKRXDART:20241106000209Canonical exit: 4 Feb 2025 (T+90)
- 13,333 sharesShareKRXDART:20241106000204Canonical exit: 4 Feb 2025 (T+90)
- 313,225 sharesShareKRXDART:20241106000191
- ShareKRXDART:20241008000360
- 541,204 sharesKRXDART:20241007000209
- ShareKRXDART:20240729000179Canonical exit: 27 Oct 2024 (T+90)
25 of 44 declarations
About 한올바이오파마
Hanall Biopharma is a company specializing in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative treatments for various diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
